Affiliation:
1. Frank Netter School of Medicine, Quinnipiac University, Hamden, CT.
Abstract
Abstract
Background
Prior studies indicate that neuroactive steroids mediate some of alcohol's effects. Dutasteride, widely used to treat benign prostatic hypertrophy, is an inhibitor of 5-alpha reductase enzymes, which play a central role in the production of 5α-reduced neuroactive steroids. The purpose of this study was to test dutasteride's tolerability and efficacy for reducing drinking.
Methods
Men (n = 142) with heavy drinking (>24 drinks per week) and a goal to either stop or reduce drinking to nonhazardous levels were randomized to placebo or 1 mg dutasteride daily for 12 weeks. We hypothesized that dutasteride-treated patients would be more successful in reducing drinking.
Results
Generalized linear mixed models that included baseline drinking, treatment, time and their 2-way interaction identified significant interactions of treatment-time, such that dutasteride treatment reduced drinking more than placebo. During the last month of treatment, 25% of dutasteride-treated participants had no hazardous drinking (no heavy drinking days and not more than 14 drinks per week) compared with 6% of placebo-treated participants (P = 0.006; NNT = 6). Sensitivity analysis identified baseline drinking to cope as a factor associated with larger reductions in drinking for dutasteride compared with placebo-treated participants. Dutasteride was well tolerated. Adverse events more common in the dutasteride group were stomach discomfort and reduced libido.
Conclusion
Dutasteride 1 mg daily was efficacious in reducing the number of heavy drinking days and drinks per week in treatment-seeking men. The benefit of dutasteride compared with placebo was greatest for participants with elevated baseline drinking to cope motives.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference61 articles.
1. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders;Lancet,2009
2. Epidemiology of dsm-5 alcohol use disorder: results from the national epidemiologic survey on alcohol and related conditions iii;JAMA Psychiatry,2015
3. Alcohol treatment utilization: findings from the national epidemiologic survey on alcohol and related conditions;Drug Alcohol Depend,2007
4. Pharmacotherapy of alcohol use disorders: seventy-five years of progress;J Stud Alcohol Drugs Suppl,2014
5. Medications for alcohol use disorders: an overview;Pharmacol Ther,2018